Insider

Intuitive Surgical Inc

ISRG Health Care · 3 analyses

Intuitive Surgical reported $3B in revenue (+21.7% YoY), compared with a +7.2% median across covered Health Care peers. 12 insider sales recorded.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Intuitive Surgical розширює склад ради директорів

Компанія Intuitive Surgical розширює раду директорів з десяти до одинадцяти осіб та призначає Аарона Мартіна незалежним директором з 1 січня 2027 року. Це кадрове рішення змінює структуру управління та супроводжується стандартним пакетом винагороди для нового члена ради.

· Intuitive Surgical Inc
Deals & ownership

Intuitive Surgical insiders sold shares in September 2026

In September 2026, two Intuitive Surgical executives sold shares under Rule 10b5‑1 plans. Mark Brosius, executive vice president and chief manufacturing and supply chain officer, sold 48 shares for $17,140.93 on September 10‑11. Fredrik Widman, vice president, corporate controller, sold 1,089 shares for $407,765.16 on September 15.

· Intuitive Surgical Inc

Company history

October 2026

INTUITIVE SURGICAL INC: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-21: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 2,162,400,000 USD (2.2 billion; 2,162 million); same period a year earlier (2025-01-01 to 2025-09-30): 2,061,200,000 USD (2.1 billion; 2,061 million); change +4.9% Source
  • 2026-10-21: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 408,300,000 USD (408 million); same period a year earlier (2025-07-01 to 2025-09-30): 329,400,000 USD (329 million); change +24% Source
  • 2026-10-21: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-30: 1,140,800,000 USD (1.1 billion; 1,141 million); same period a year earlier (2025-01-01 to 2025-09-30): 958,900,000 USD (959 million); change +19% Source
  • 2026-10-21: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 3,197,000,000 USD (3.2 billion; 3,197 million); same period a year earlier (2025-01-01 to 2025-09-30): 2,138,000,000 USD (2.1 billion; 2,138 million); change +49.5% Source
  • 2026-10-21: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 2,978,100,000 USD (3 billion; 2,978 million); previous balance (2025-12-31): 3,368,000,000 USD (3.4 billion; 3,368 million); change -11.6% Source
  • 2026-10-21: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 15,986,200,000 USD (16 billion; 15,986 million); previous balance (2025-12-31): 17,824,000,000 USD (17.8 billion; 17,824 million); change -10.3% Source
  • 2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 3,048,700,000 USD (3 billion; 3,049 million); same period a year earlier (2025-07-01 to 2025-09-30): 2,505,100,000 USD (2.5 billion; 2,505 million); change +21.7% Source
  • 2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-30: 8,711,800,000 USD (8.7 billion; 8,712 million); same period a year earlier (2025-01-01 to 2025-09-30): 7,198,500,000 USD (7.2 billion; 7,199 million); change +21% Source
  • 2026-10-21: Gross profit (us-gaap:GrossProfit), quarter 2026-07-01 to 2026-09-30: 2,084,300,000 USD (2.1 billion; 2,084 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,662,400,000 USD (1.7 billion; 1,662 million); change +25.4% Source
  • 2026-10-21: Gross profit (us-gaap:GrossProfit), year to date 2026-01-01 to 2026-09-30: 5,875,200,000 USD (5.9 billion; 5,875 million); same period a year earlier (2025-01-01 to 2025-09-30): 4,738,000,000 USD (4.7 billion; 4,738 million); change +24% Source
  • 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 592,600,000 USD (593 million); same period a year earlier (2025-07-01 to 2025-09-30): 759,700,000 USD (760 million); change -22% Source
  • 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 2,419,800,000 USD (2.4 billion; 2,420 million); same period a year earlier (2025-01-01 to 2025-09-30): 2,081,200,000 USD (2.1 billion; 2,081 million); change +16.3% Source

September 2026

INTUITIVE SURGICAL INC: 3 recorded developments from 3 official sources in 2026-09.

  • Summary: S (open market or private sale): 2 transaction(s) on 2026-09-10 to 2026-09-11, 48 disposed, total value 17,140.93 USD at a weighted average price of 357.1027 USD; owned after the last one: 764 Source
  • 2026-09-15: Units to be sold: 2178; aggregate market value: 823153.32 USD; units outstanding: 353278038 Source
  • 2026-09-16: Summary: S (open market or private sale): 2 transaction(s) on 2026-09-15, 1,089 disposed, total value 407,765.16 USD at a weighted average price of 374.44 USD; owned after the last one: 1,026 Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 21, 2026. SEC

LatestEarlierChange
Revenue quarter$3B$2.5B+21.7%
Operating income quarter$593M$760M-22.0%
Net income quarter$523M$704M-25.8%
Diluted EPS quarter$1.49$1.95-23.6%
Operating cash flow year to date$3.2B$2.1B+49.5%
Cash and cash equivalents balance$3B$3.4B-11.6%

Next results expected around January 20, 2027 (estimate: the quarter ending about December 30, 2026 plus the 21 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Intuitive Surgical Inc ISRG$3B+21.7%19.4%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
November 2, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 10, 2026Gary LoebSale 10b5-1 plan notice filed400$458.15$183,260SEC
November 4, 2026Gary S GuthartSale 10b5-1 plan10,000$457.34$4,573,370SEC
November 4, 2026Craig H BarrattSale 10b5-1 plan notice filed1,150$460.00$529,003SEC
October 30, 2026Fredrik WidmanSale 10b5-1 plan5,448$436.06$2,375,628SEC
October 30, 2026Fredrik WidmanPlanned sale 10b5-1 plan4,359—$1,956,145SEC
October 30, 2026Mark BrosiusSale 10b5-1 plan124$450.77$55,896SEC
October 28, 2026Mark BrosiusSale 10b5-1 plan183$448.33$82,044SEC
October 23, 2026Guthart Family TrustPlanned sale 10b5-1 plan27,139—$12,045,645SEC
October 23, 2026Gary S GuthartSale 10b5-1 plan20,095$451.61$9,075,137SEC
October 23, 2026Fredrik WidmanSale 10b5-1 plan notice filed4,047$453.21$1,834,124SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock29,561,783$12,020,707,694-1.5%Q3 2026
State Street16,173,422$6,576,598,588+0.7%Q3 2026
Geode Capital Management8,542,334$3,458,144,928+0.1%Q3 2026
Norges Bank (Norway's sovereign fund)4,954,874$1,970,454,292—Q2 2026
Wellington Management3,352,466$1,363,213,250-11.8%Q3 2026
Fidelity (FMR)2,310,391$939,474,527-45.7%Q3 2026
Capital Research Global Investors2,208,824$898,174,103+42.4%Q3 2026
Citadel Advisors1,370,412$557,250,632+191.5%Q3 2026
Renaissance Technologies456,411$185,590,405-9.5%Q3 2026
Two Sigma Investments407,249$165,599,661-79.4%Q3 2026
ARK Investment Management (Cathie Wood)74,399$30,252,865+5.7%Q3 2026
Millennium Management13,020$5,294,323-96.9%Q3 2026
D. E. Shaw & Co.12,847$5,223,976-96.2%Q3 2026
Bridgewater Associates11,560$4,700,643-40.2%Q3 2026
T. Rowe Price9,945,424$4,044,108-11.6%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.